Epic’s Comprehensive Cancer Profiling™ now includes the broadest ctDNA assay PredicineATLAS™ Predicine, a molecular insights company headquartered in Hayward, California and Epic Sciences, Inc. today announced they have entered into a global strategic partnership to offer biopharmaceutical companies access to both Predicine’s ctDNA-based testing and Epic’s CTC-based testing. Predicine’s lead offering is PredicineATLAS™, the...
Predicine will host a satellite symposium at the 2020 International Society of Liquid Biopsy (ISLB) Virtual Congress to discuss the clinical utility of circulating cell-free DNA and RNA liquid biopsy tests with a focus on MRD and early cancer detection. This symposium will bring together biomarker experts from Merck KGaA, Darmstadt, Germany, Washington University, and...
Predicine is excited to partner with Canadian Cancer Trials Group (CCTG) and contribute to a European Society for Medical Oncology (ESMO) featured presentation in pancreatic cancer. PredicineATLAS, a 600-gene cfDNA assay, is utilized in the CCTG PA.7 trial to assess the predictive value of blood TMB in metastatic pancreatic ductal adenocarcinoma patients treated with Durvalumab...
Date: June 22-24, 2020 Location: Virtual Predicine will present three e-posters focusing on liquid biopsy methylation, urine biomarkers, and cfDNA+cfRNA molecular profiling, at the American Association for Cancer Research Virtual Meeting II, taking place June 22-24, 2020. For the first time, Predicine will present its proprietary methylation cell-free DNA (cfDNA) liquid biopsy technology for...
Date: May 29 – 31, 2020 Location: Virtual In collaboration with Northwestern University and Peking University Cancer Hospital, we are presenting a poster at the American Society of Clinical Oncology Virtual Scientific Program. This study demonstrates that PredicineCARE blood-based ctDNA effectively detected the key mutations in HR+ metastatic breast cancer patients in US and...
This unprecedented time is especially troubling for people fighting with cancer. At Predicine, our primary focus remains our commitment to deliver genomic testing to physicians and cancer patients in need. Our global labs in San Francisco and Shanghai remain open and operational with precautionary measures put in place to ensure we are keeping our employees safe as...
September 27 – October 1, 2019 Barcelona, Spain Poster presentation: Peripheral cytotoxic T cell correlates with tumor mutational burden and is predictive for progression free survival in advanced breast cancer
August 20 – 22, 2019 Washington DC Details: Exhibition booth # 205 Presentation: Reshaping Oncology Drug Development Landscape with ctDNA + ctRNA Liquid Biopsy Solutions | August 20, 2019
May 31-June 4, 2019 Chicago, IL Details: Exhibition booth #19135 Satellite symposium: New Era of Biomarker-driven Clinical Trials and Regulatory Approvals in US and China |June 1, 2019 Poster Presentations: Plasma cell free DNA (cfDNA) based somatic aberrations detected in treatment naïve metastatic hormone sensitive prostate cancer (mHSPC), hormonally ablated mHSPC and metastatic castration resistant...
